Mesaflor

Mesalazine, the active ingredient in Mesaflor, is a 5-aminosalicylic acid (5-ASA) derivative presented as an oral tablet for oral use. It is employed to reduce inflammation in the colon of patients with ulcerative colitis and Crohn's disease.

GNH USA supplies Mesaflor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesaflor belongs to the 5‑ASA class and is used to manage inflammatory bowel disease.

Ulcerative colitis: reduces colonic inflammation and helps induce and maintain remission. Crohn's disease (colonic involvement): controls inflammation and alleviates symptoms. Maintenance therapy: sustains remission in ulcerative colitis after induction of response.

Mesaflor may cause a range of adverse reactions.

Common Side Effects: - Nausea - Abdominal pain or cramping - Headache - Flatulence or bloating

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reaction (e.g., Stevens‑Johnson syndrome) - Blood dyscrasias such as neutropenia or agranulocytosis - Elevated liver enzymes or hepatitis - Myocarditis or pericarditis - Acute worsening of colitis

Before prescribing Mesaflor, clinicians should consider several safety measures.

Monitor renal function: assess baseline creatinine and adjust if impairment occurs. Monitor hepatic function: check liver enzymes periodically. Assess disease activity: ensure active inflammation is present before initiation. Avoid in known hypersensitivity: discontinue if allergic reaction develops. Use caution in pregnancy and breastfeeding: benefits must outweigh potential risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mesaflor can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: enhanced anticoagulant effect, may raise INR. - Sulfasalazine: additive toxicity, especially gastrointestinal.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Diuretics: may affect renal clearance, monitor electrolytes.